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Background: Hepatic ischemiareperfusion injury is a common clinical problem in hepatic surgery and
transplantation. Several cellular and tissue structural and functional alterations are observed in such injury.
The aim of this study was to evaluate the effect of dexmedetomidine on lipid peroxidation and erythrocyte
deformability during ischemiareperfusion injury in rats.
Methods: Twenty-four Wistar Albino rats were randomly separated into three groups as control (C),
ischemiareperfusion injury (I/R) and dexmedetomidine group (I/R-D). Ischemia was induced with portal
clampage for 45 min and reperfusion period was 45 min after declampage. Group I/R-D received
dexmedetomidine 100 mg/kg i.p. 30 min before portal clampage. Serum malondialdehyde and superoxide
dismutase activities to document lipid peroxidation and erythrocyte deformability index were investigated.
Results: Serum superoxide dismutase and malondialdehyde activity levels were significantly higher and
erythrocyte deformability index was decreased in hepatic ischemiareperfusion group. However, these changes
were observed to be prevented with dexmedetomidine treatment when given before portal clampage.
Conclusion: These findings clearly indicate that erythrocyte deformability index is decreased in hepatic
ischemia reperfusion injury and has a potential role to prevent these alterations. The protective effect of
dexmedetomidine on hepatic I/R injury is also decreased lipid peroxidation. Further experimental and clinical
investigations may clarify the molecular mechanisms and clinical significance of these findings.
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H
epatic ischemiareperfusion (I/R) injury is
a common problem in trauma, hepatic surgery,
and transplantation. Previous clinical and ex-
perimental studies have investigated several aspects of
this clinical entity (14). Hepatic I/R injury is known
to be a result of a complex mechanism which in-
volves different cellular and molecular elements such as
leukocytes, red blood cells (RBC), TNFa,N O ,N F
kappaB, and the others (2). Oxidative stress, free radical
formation and lipid peroxidation, which play important
roles in development of I/R injury, also cause membrane
changes in RBCs (5). Erythrocyte deformability is
crucial for the maintenance of normal circulation.
Optimal deformability facilitates the passage of RBC
through narrow capillaries in the microcirculation and
reduces blood viscosity at high shear rates in large blood
vessels (6).
Dexmedetomidine, a selective and potent a2-adrenoceptor
agonist, was approved by the US Food and Drug Ad-
ministration in 1999 for sedation of patients hospitalized
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research articles have emerged reporting other possible
indications, such as regional and general anesthesia (7, 8).
Dexmedetomidine was reported to be effective in protect-
ing against focal ischemia in rabbits, in cardiac I/R injury
in rats in kidney I/R injury in rats, and in incomplete
forebrain ischemia in rats (912). Despite its increased
clinical use, frequently in critically ill patients, the effect
of dexmedetomidine on liver I/R injury has not been yet
investigated (13).
The primary aim of this study was to investigate
hepatic I/R injury induced changes in erythrocyte
deformability and the preventive role of dexmedetomi-
dine on increased lipid peroxidation and erythrocyte
deformability alterations in experimental hepatic I/R
injury.
Materials and methods
Animals and experimental protocol
The experiments were performed in adherence to
National Institutes of Health guidelines on the use of
experimental animals. Twenty-four male Wistar rats
weighing from 275 to 350 g were housed at constant
temperature with 14/10 h periods of light and dark
exposure. Animals were allowed access to standard rat
chow and water ad libitum during an acclimatation
period of at least 5 days prior to use in these experiments.
Approval of the Institutional Ethics Committee was
obtained. The experiments were performed in the Animal
Experimental Laboratory of the Physiology Department
in Kirikkale University.
Rats were anesthetized with intramuscular ketamine
50 mg/kg. The chest and abdomen were shaved and each
animal was fixed in a supine position on the operating
table. The abdomen was cleaned with 1% polyvinyl
iodine and when dry, the operating field was covered
with a sterile drape and median laparotomy was per-
formed. There were three experimental groups (Group C
(sham-control; n8), Group I/R (ischemia-reperfusion,
n8), and Group I/R-D (I/R-Dexmedetomidine; n8)).
Sham operation was performed on the rats in
Group A. The sham operation consisted of mobilization
of the hepatic pedicle only. The rats in this group were
sacrificed 90 min after the procedure. Hepatic I/R injury
was induced in Groups I/R and I/R-D, respectively with
hepatic pedicle clampage using a vascular clamp as
in the previous study of Yaylak et al. (3). After an
ischemia period of 45 min, the vascular clamp was
removed. A reperfusion period was maintained for
45 min. In Group I/R-D, dexmedetomidine hydrochlo-
ride 100 mg/kg, (Precedex 100 mg/2 ml, Abbott†, Abbott
Laboratory, North Chicago, IL, USA) was administrated
via intraperitoneal route 30 min before clampage (14).
All the rats were given ketamine 100 mg/kg intraper-
itoneally and intracardiac blood samples were obtained.
Heparinized total blood samples were used to prepare
erythrocyte packs. Deformability measurements were
done using erythrocyte suspensions with 5% hematocrit
in phosphate buffered saline (PBS) buffer.
Biochemical measurements
Blood samples with etylenediamine tetra acetic acid were
centrifuged and plasma was stored at 808C until the
day of study. Experiments were studied at the upper
phase obtained after centrifugation. Superoxide dismu-
tase (SOD) and malondialdehyde (MDA) levels in plasma
were measured biochemically.
Deformability measurements
Erythrocyte deformability was measured using a constant
flow filtrometer system (MP 30, Biopac Systems Inc.,
Commat, USA). Erythrocyte suspension that was deliv-
ered at 1 ml/min flow rate was passed through a
nucleopore-polycarbonate filter of 5 mm in diameter, and
alterations in the filtration pressure corresponding to
different flow rates were measured. The alterations in the
pressure were transferred to computer medium with an
MP 30 data equation system. The ratio of the values of
filtration pressure for the cellular suspension and buffer
were calculated, and the relative resistance was calculated.
Statistical analysis
Statistical Package for the Social Sciences (SPSS,
Chicago, IL, USA) 12.0 program was used for statistical
analysis. Variations in plasma oxidative state parameters
and erythrocyte deformability between study groups were
assessed by using KruskalWallis test. Bonferroni ad-
justed MannWhitney U test was used after significant
KruskalWallis to determine which group differs from
the other. Results were expressed as mean9standard
deviation (Mean9SD). Statistical significance was set at
a p-value B0.05 for all analyses and pB0.033 (0.1/3) for
Bonferroni adjusted MannWhitney U test.
Results
Relative resistance, which reflects erythrocyte deform-
ability, was increased in Group I/R. Deformability index
was higher in I/R group than the other groups (Group
CGroup I/R p0.005; Group I/RGroup I/R-D
p0.028), (Fig. 1). However, with dexmedetomidine
treatment deformability index was found to be similar
with the (Groups C and I/R-D, p0.574).
MDA activity was higher in I/R group than the other
groups(GroupCGroupI/Rp0.027;GroupI/RGroup
I/R-D p0.011) (Fig. 2). SOD activity was also higher in
I/R group than the control group (Group CGroup I/R
p0.029), (Fig. 3). However, dexmedetomidine treatment
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levels with the control group (Figs. 2 and 3).
Discussion
Hepatic I/R injury is defined as the prolongation and
aggravation of ischemic tissue damage with reperfusion
(15). Several cellular and molecular changes in hepatic
I/R injury have been investigated in clinical and experi-
mental studies. However, in this study, we have reported
(for the first time, to our knowledge) the protective
effect of dexmedetomidine on erythrocyte deformability
alterations in experimental hepatic I/R injury model in
the rat. Dexmedetomidine, which is a highly potent and
selective a2-adrenoreceptor agonist, was administered
before induction of ischemia, and resulted in decreased
SOD and MDA levels, which are known to play crucial
role in development of hepatic I/R injury.
Hepatic I/R injury induced lipid peroxidation generates
a complex variety of products. Many of these react with
several protein products and DNA and causes local and
systemic toxic and mutagenic effects (16). A major target
site of lipid peroxidation is the cellular membrane, which
contains polyunsaturated fatty acids. Toxicity of partially
reduced oxygen species arises from the peroxidation of
polyunsaturated fatty acid of membrane phospholipids.
The final event leading to structural and functional tissue
damage is the loss of disintegration of cellular membrane.
In hepatic I/R injury this mechanism is exacerbated after
reperfusion with microcirculatory derangements and
altered mitochondrial functions (17).
Fig. 1. Comparison of the Mean9SD erythrocyte deformability values between the groups (MannWhitney U test, Group
CGroup I/R p0.005; Group I/RGroup I/R-D p0.028).
Note: *pB0.05 compared to the Group C; **pB0.05 compared to the Group I/R.
Fig. 2. Comparison of the Mean9SD malondialdehyde (MDA; nmol/mg) levels between the groups (MannWhitney U test,
Group CGroup I/R p0.027; Group I/RGroup I/R-D p0.011).
Note: *pB0.05 compared to the Group C; **pB0.05 compared to the Group I/R.
Hepatic ischemia reperfusion injury
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changes and may be altered with the changes in tissue
perfusions due to several factors: such as bleeding, sepsis,
and cardiovascular problems. Disorders in the hemato-
logical state may result with changes plasma viscosity
(18). Erythrocyte deformability and plasma viscosity are
important factors that affect organ and tissue perfusion
(19). Optimal delivery of oxygen and vital molecules to
the final organ capillaries and clearance of metabolic
wastes, erythrocytes must be able to extend and curve,
and have the capability to move in these areas. This
capacity is termed as ‘deformability’ (20). There is
equilibrium in free radical production and antioxidant
defense system that suppress production of oxygen free
radical in the body. Oxidative damages occur when this
equilibrium is disrupted. Increased lipid peroxidation is
also one of the results of increased oxidative stress (21).
It was reported that, some parameters of erythrocyte
functions and membrane integrity were impaired in
increased lipid peroxidation in vivo and in vitro studies
(22). The products that arise due to lipid peroxidation
associated with increased oxidative stress significantly
affect membrane permeability and micro viscosity. Thus,
diminished deformability capacity and survival of the
erythrocytes are observed (23). SOD, CAT, and GSH-
Px are responsible in cellular antioxidant defense me-
chanisms. These enzymes eliminate superoxide anions
and hydrogen peroxides, and prevent free radical produc-
tion (24). SOD is the primary defensive enzyme against
oxygen derived free radical production and catalyses
H2O2 conversion O

2 (25). Oxygen radicals generated
in response to I/R have been implicated in the micro
vascular dysfunction and parenchymal cell injury of
the intestine and liver (26, 27). The TBA assay, which
measures MDA, is a simple and easy-to-use method for
assessment of the degree of injury attributable to the
free radicals produced by ischemia/reperfusion, and is
frequently used in laboratory (28). In vitro treatment
of the erythrocytes with MDA has been reported to result
with decreased erythrocyte deformability and survival
(23, 25, 29, 30). In this current study, increased
MDA levels were accompanied with decreased erythro-
cyte deformability index in hepatic I/R group. Dexmede-
tomidine treatment was also observed to protective
against increased MDA production in hepatic I/R injury.
Also this finding was considered significant, which may
explain the protection of erythrocyte deformability with
dexmedetomidine treatment prior to hepatic ischemia.
Erythrocyte deformability and erythrocyte membrane
rigidity were reported to be affected with several agents
that induce lipid peroxidation. In this study, dexmedeto-
midine treatment was shown to have protective
effects against hepatic I/R injury induced erythrocyte
deformability changes. Altered erythrocyte deformability
not only changes the oxygen delivery capacity of the
erythrocytes but also the survival of the circulating
erythrocytes (22, 23).
As a conclusion the results of this study clearly
demonstrate that erythrocyte deformability is signifi-
cantly altered in experimental hepatic I/R injury in the
rat. Increased SOD and MDA production, which causes
lipid peroxidation and cellular membrane alterations may
play an important role in erythrocyte deformability
alterations. In addition, dexmedetomidine was observed
to protect against these alterations in hepatic I/R injury,
when given before induction of ischemia. Other aspects of
these findings including clinical significance and practical
applications, merit further experimental and clinical
investigation.
Fig. 3. Comparison of the Mean9SD levels of superoxide dismutase (SOD; U/mg) between the groups (MannWhitney U test,
Group CGroup I/R p0.029; Group I/RGroup I/R-D p0.108).
Note: *pB0.05 compared to the Group C.
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